Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The hemolytic uremic syndromes.

Jessica Caprioli1, Li Peng, Giuseppe Remuzzi

  • 1Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Bergamo, Italy. caprioli@marionegri.it

Current Opinion in Critical Care
|September 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Journal of the American Society of Nephrology : JASN·2015
Same author

International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology.

Lancet (London, England)·2015
Same author

Rare diseases and effective treatments: are we delivering?

Lancet (London, England)·2015
Same author

Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts.

Stem cell reports·2015
Same author

Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury.

Scientific reports·2015
Same author

Need for chronic kidney disease prevention programs in disadvantaged populations.

Clinical nephrology·2015

Recent advances reveal Shiga toxins and complement system gene mutations in hemolytic uremic syndrome (HUS). Understanding these molecular mechanisms guides new clinical strategies for HUS patients.

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Hemolytic uremic syndrome (HUS) is a serious condition with complex molecular underpinnings.
  • Recent research has significantly improved our understanding of HUS pathogenesis.

Purpose of the Study:

  • To review biochemical and genetic data related to hemolytic uremic syndromes.
  • To explore how this knowledge can inform novel clinical approaches for HUS management.

Main Methods:

  • Literature review of biochemical and genetic studies on HUS.
  • Analysis of Shiga toxin mechanisms and complement system gene mutations.

Main Results:

  • Shiga-like toxin-1 and Shiga-like toxin-2 roles in regulating immune response genes elucidated.

Related Experiment Videos

  • Mutations in complement regulatory genes (factor H, membrane cofactor protein, factor I) identified in non-Shiga-like toxin HUS.
  • Reduced complement regulation may lead to glomerular endothelial cell damage.

    • Conclusions:

    • Distinct molecular pathways, including Shiga toxins and complement dysregulation, contribute to HUS.
    • Clinical outcomes and treatment strategies vary significantly based on the underlying cause of HUS.
    • Kidney transplantation offers a good prognosis for some HUS patients, but recommendations differ based on etiology.